Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension
暂无分享,去创建一个
S. Rich | R. Barst | D. Badesch | A. Frost | M. Mcgoon | V. McLaughlin | V. Tapson | R. Oudiz | L. Rubin | S. Gaine | R. Bourge | J. Sigman | I. Robbins | C. Arneson | S. Blackburn | R. Roscigno | M. McGoon
[1] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[2] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[3] S. Rich,et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.
[4] B. Brundage,et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. , 1997, Journal of the American College of Cardiology.
[5] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[6] J. Sailstad,et al. The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15AU81 in the anesthetized beagle dog. , 1993, Prostaglandins, leukotrienes, and essential fatty acids.
[7] M. Mata,et al. The effects of 15AU81, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensis systems of anesthetized dogs , 1991 .
[8] E H Bergofsky,et al. Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.